The Role and Mechanism of Vimentin in Sepsis Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03253146

Enrollment

200

Registered

2017-08-17

Start date

2016-07-01

Completion date

2017-12-31

Last updated

2017-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

Vimentin, sepsis, immune cells, apoptosis

Brief summary

Sepsis is the most common cause of death in the clinical critically ill patients. We have successfully screened the sepsis biomarkers by clinical proteomics approach and found that Vimentin (VIM) played an important role in the occurrence and development of sepsis. However, the exact mechanism is remaining unclear. In this study, the relationship between the changes of peripheral circulation VIM expression and different stages of sepsis development will be further verified in lager clinical trials, as well as the relationship between VIM expression and apoptosis of immune cells (e.g lymphocytes) will also be clarified. This may indicate that the role of VIM in the cell-mediated immunity apoptosis and inflammation-related pathways. Through the implementation of this study, we can clarify the clinical value of VIM and the mechanism of VIM-mediated immune cell apoptosis during the sepsis development from the molecular level, and determine whether the VIM as a new target for sepsis diagnosis and treatment.

Interventions

DIAGNOSTIC_TESTVIM detection

VIM expression in serum and lymphocytes detection

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

Sepsis 3.0 was adopted to selected participants

Exclusion criteria

Participants were excluded if they were younger than 18 years of age; contracted acquired immunodeficiency syndrome; had reduced polymorphonuclear granulocyte counts (\<500 μL-1); died within 24 h after admission to the ICU; refused to participate in the study; or declined treatment during the period of observation.

Design outcomes

Primary

Measure	Time frame	Description
28-day survival	28-day	The survival time of patients more than 28days is defined as survival. The survival time of patients less than 28days is defined as death.

Countries

China

Contacts

Primary ContactDawei Liu, MD

dwliu98@126.com+86 10 69152305

Backup ContactLongxiang Su, MD

slx77@163.com+86 10 69152300

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026